Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

BACKGROUND: Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early SIT intro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Abu-Sbeih, Hamzah, Ali, Faisal S., Wang, Xuemei, Mallepally, Niharika, Chen, Ellie, Altan, Mehmet, Bresalier, Robert S., Charabaty, Aline, Dadu, Ramona, Jazaeri, Amir, Lashner, Bret, Wang, Yinghong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444537/
https://ncbi.nlm.nih.gov/pubmed/30940209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0577-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller